Can direct oral anticoagulants be used in kidney transplant recipients?

Kathrine ParkerJanette ChuMuir MortonShiv BhutaniMichael PictonSandip MitraJecko Thachil

Published in: Clinical transplantation (2021)

There was no evidence of a significant interaction of apixaban or rivaroxaban with CNIs based on expected DOAC and CNI levels. Their use was found to be safe and effective with no VTE events and bleeding episodes similar to published trial data.

Keyphrases

direct oral anticoagulants
venous thromboembolism
atrial fibrillation
study protocol
phase iii
electronic health record
clinical trial
phase ii
randomized controlled trial
meta analyses
open label
data analysis
systematic review
artificial intelligence